NASTA, Paola
 Distribuzione geografica
Continente #
NA - Nord America 1.033
EU - Europa 293
AS - Asia 195
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
SA - Sud America 1
Totale 1.527
Nazione #
US - Stati Uniti d'America 1.024
CN - Cina 144
UA - Ucraina 107
DE - Germania 54
HK - Hong Kong 36
FI - Finlandia 32
IT - Italia 32
GB - Regno Unito 26
IE - Irlanda 16
IN - India 11
FR - Francia 10
CA - Canada 9
BE - Belgio 8
SE - Svezia 6
EU - Europa 4
SG - Singapore 2
AL - Albania 1
AR - Argentina 1
AU - Australia 1
KZ - Kazakistan 1
NL - Olanda 1
TR - Turchia 1
Totale 1.527
Città #
Fairfield 148
Woodbridge 134
Ashburn 109
Jacksonville 87
Wilmington 65
Ann Arbor 61
Seattle 57
Chandler 56
Houston 47
Cambridge 46
Hong Kong 36
Nanjing 32
Princeton 32
Beijing 28
Dearborn 22
Helsinki 21
New York 17
Dublin 16
Washington 13
Changsha 12
Nanchang 11
Toronto 9
Brussels 8
Jiaxing 8
Jinan 8
Lancaster 8
Milan 8
San Diego 8
Shenyang 7
Tianjin 7
Hebei 5
Los Angeles 5
Monmouth Junction 5
Des Moines 4
Ningbo 4
San Francisco 4
Shanghai 4
Brescia 3
Zhengzhou 3
Chiswick 2
Leawood 2
London 2
Polaveno 2
Ronciglione 2
San Mateo 2
Taiyuan 2
Taizhou 2
Augusta 1
Berlin 1
Boardman 1
Charlotte 1
Como 1
Dallas 1
Eindhoven 1
Fuzhou 1
Guangzhou 1
Gunzenhausen 1
Haikou 1
Hefei 1
Kocaeli 1
Kunming 1
Lanzhou 1
Melbourne 1
Orange 1
Pescara 1
Pune 1
Redmond 1
Rochester 1
Shaoxing 1
Tirana 1
Verona 1
Walnut 1
Totale 1.199
Nome #
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 132
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 121
Imported malaria in an HIV-positive traveler. A case-report with a fatal outcome 120
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. 114
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 112
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 110
HYALURONIC ACID AND LIVER STIFFNESS REDUCTION IN HIV-HEPATITIS-C (HCV) COINFECTED PATIENTS TREATED WITH A CCR5 INHIBITOR MARAVIROC (MVC) IN A RANDOMIZED CONTROLLED TRIAL (MAICOL STUDY-48-WEEK ANALYSIS) 106
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 99
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 97
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 95
Access to antiretroviral therapy and disease progression in HIV+ migrants in Brescia, Italy 81
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 75
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 67
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 66
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 64
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 57
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection 42
Totale 1.558
Categoria #
all - tutte 6.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.017


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201981 0 0 0 0 0 0 0 0 0 0 41 40
2019/2020435 54 12 18 51 25 49 50 44 28 66 14 24
2020/2021249 2 26 18 48 11 26 7 27 30 24 23 7
2021/2022162 24 15 5 9 2 11 4 14 7 17 20 34
2022/2023165 21 2 1 15 10 45 0 18 32 2 7 12
2023/2024188 11 7 31 17 18 52 5 6 37 4 0 0
Totale 1.558